Novacta Therapeutics, a UK-based anti-infectives company, today announced that the UK's Defence Science and Technology Laboratory (DSTL) will evaluate its proprietary lantibiotics as a broad spectrum antiviral treatment. Using its technology, Novacta intends to generate new compounds with improved activity against influenza and other viral targets. DSTL will conduct efficacy studies to measure the ability of the lantibiotics to treat or prevent viral infections.   more »